1. Market Research
  2. > Geron Corporation – Product Pipeline Review – 2013

Geron Corporation – Product Pipeline Review – 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 113 pages

Geron Corporation – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Geron Corporation - Product Pipeline Review - 2013” provides data on the Geron Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Geron Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from Geron Corporation and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Geron Corporation - Brief Geron Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Geron Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Geron Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Geron Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Geron Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Geron Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Geron Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Geron Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Geron Corporation and identify potential opportunities in those areas.

Table Of Contents

Geron Corporation - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Geron Corporation Snapshot 6
Geron Corporation Overview 6
Key Information 6
Key Facts 6
Geron Corporation - Research and Development Overview 7
Key Therapeutic Areas 7
Geron Corporation - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Geron Corporation - Pipeline Products Glance 12
Geron Corporation Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Geron Corporation - Early Stage Pipeline Products 14
Pre-Clinical Products/Combination Treatment Modalities 14
Geron Corporation - Drug Profiles 15
GRN-510 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
GRN-665 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
GRN163L + Paclitaxel + Carboplatin 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
imetelstat sodium 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Geron Corporation - Pipeline Products by Route of Administration 22
Geron Corporation - Pipeline Products By Mechanism of Action 23
Geron Corporation - Recent Pipeline Updates 24
Geron Corporation - Dormant Projects 31
Geron Corporation - Discontinued Pipeline Products 32
Discontinued Pipeline Product Profiles 32
GRN-1005 32
GRN163L + Paclitaxel + Bevacizumab 32
GRNCHND-1 33
GRNCM-1 33
GRNIC-1 33
GRNOPC-1 33
GRNVAC-1 33
GRNVAC-2 34
Hepatocytes For Liver Failure 34
imetelstat sodium 34
Osteoblasts For Osteoporosis 34
V-935 34
Geron Corporation - Company Statement 36
Geron Corporation - Locations And Subsidiaries 40
Head Office 40
Other Locations and Subsidiaries 40
Geron Corporation, Recent Developments 41
Geron Corporation- Press Release 41
Apr 09, 2013: Geron Announces Presentation Of Phase II Study Results Of Imetelstat At AACR Annual Meeting 2013 41
Dec 06, 2010: Geron Presents Clinical Data On Telomerase Vaccine At 2010 American Society Of Hematology Meeting 41
Dec 02, 2010: Geron Initiates Randomized Phase II Clinical Trial Of Imetelstat In Breast Cancer 43
Nov 11, 2010: Geron Announces Two Publications Demonstrating That Telomerase Inhibitor Drug Targets Cancer Stem Cells 44
Oct 11, 2010: Geron Initiates Clinical Trial Of Human Embryonic Stem Cell-Based Therapy 46
Jul 30, 2010: Geron To Proceed With Human Clinical Trial Of GRNOPC1 In Patients With Acute Spinal Cord Injury 47
Jul 19, 2010: Geron Initiates Randomized Phase II Clinical Trial Of Imetelstat In Non-Small Cell Lung Cancer Patients 47
Jun 07, 2010: Angiochem Presents Complete Phase I/II Clinical Data Of ANG1005 For Treatment Of Brain Metastases 48
Jun 07, 2010: Angiochem Presents Complete Phase I/II Clinical Data Of ANG1005 For Treatment Of Glioblastoma 49
Jun 07, 2010: Geron Presents Clinical Data On Telomerase Inhibitor Drug In Breast Cancer At ASCO 49
May 19, 2010: Geron Reports Positive Data On TAT153 In Model Of Idiopathic Pulmonary Fibrosis 50
May 13, 2010: Geron Annonces Positive Preclinical Study Data On GRNCM1 51
Apr 20, 2010: Angiochem Presents Preclinical Data On ANG1005 For Treatment Of Brain Cancer 52
Mar 03, 2010: Geron Gives Five Presentations On Telomerase Inhibitor Imetelstat At The AACR Annual Meeting 53
Financial Deals Landscape 56
Geron Corporation, Deals Summary 56
Geron Corporation, Pharmaceuticals and Healthcare, Deal Details 58
Partnerships 58
Geron Enters Into Research Collaboration With Angiochem 58
Geron Enters Into Collaboration With University Campus Suffolk 83
Geron Amends Co-Development Agreement With CXR Biosciences 84
Licensing Agreements 85
GE Healthcare Expands Licensing Agreement With Geron For Stem Cell Assays 85
Geron Enters Into Licensing Agreement With Angiochem 87
Geron Enters Into Licensing Agreement With The University of Edinburgh 89
GE Healthcare Enters Into Licensing Agreement With Geron For Stem Cell Assay Products 90
Geron Enters Into Licensing Agreement With Stemcell Technologies 91
Geron Signs Licensing Agreement With Sienna 92
Geron Signs Licensing Agreement With Asia Biotech 93
Equity Offering 94
Geron Announces Public Offering Of Shares For Up To $50 Million 94
Geron Completes Public Offering Of $100 Million 96
Geron Completes Private Placement Of $10 Million 98
Geron Completes Private Placement Of $3.6 Million 100
Geron Completes Public Offering Of $47.85 Million 102
Geron Raises $15 Million Upon Exercise Of Warrants 104
Geron Completes Private Placement Of $42.38 Million 106
Asset Transactions 108
BioTime To Acquire Stem Cell Cell Assets From Geron 108
Acquisition 110
Geron Acquires Additional 25% Stake In TA Therapeutics 110
Appendix 112
Methodology 112
Coverage 112
Secondary Research 112
Primary Research 112
Expert Panel Validation 112
Contact Us 113
Disclaimer 113



List of Tables

Geron Corporation, Key Information 6
Geron Corporation, Key Facts 6
Geron Corporation - Pipeline by Indication, 2013 8
Geron Corporation - Pipeline by Stage of Development, 2013 9
Geron Corporation - Monotherapy Products in Pipeline, 2013 10
Geron Corporation - Combination Treatment Modalities in Pipeline, 2013 11
Geron Corporation - Phase II, 2013 12
Geron Corporation - Phase I, 2013 13
Geron Corporation - Pre-Clinical, 2013 14
Geron Corporation - Pipeline By Route of Administration, 2013 22
Geron Corporation - Pipeline Products By Mechanism of Action, 2013 23
Geron Corporation - Recent Pipeline Updates, 2013 24
Geron Corporation - Dormant Developmental Projects,2013 31
Geron Corporation - Discontinued Pipeline Products, 2013 32
Geron Corporation, Subsidiaries 40
Geron Corporation, Deals Summary 56
Geron Enters Into Research Collaboration With Angiochem 58
Geron Enters Into Collaboration With University Campus Suffolk 83
Geron Amends Co-Development Agreement With CXR Biosciences 84
GE Healthcare Expands Licensing Agreement With Geron For Stem Cell Assays 85
Geron Enters Into Licensing Agreement With Angiochem 87
Geron Enters Into Licensing Agreement With The University of Edinburgh 89
GE Healthcare Enters Into Licensing Agreement With Geron For Stem Cell Assay Products 90
Geron Enters Into Licensing Agreement With Stemcell Technologies 91
Geron Signs Licensing Agreement With Sienna 92
Geron Signs Licensing Agreement With Asia Biotech 93
Geron Announces Public Offering Of Shares For Up To $50 Million 94
Geron Completes Public Offering Of $100 Million 96
Geron Completes Private Placement Of $10 Million 98
Geron Completes Private Placement Of $3.6 Million 100
Geron Completes Public Offering Of $47.85 Million 102
Geron Raises $15 Million Upon Exercise Of Warrants 104
Geron Completes Private Placement Of $42.38 Million 106
BioTime To Acquire Stem Cell Cell Assets From Geron 108
Geron Acquires Additional 25% Stake In TA Therapeutics 110



List of Figures

Geron Corporation - Pipeline by Indication, 2013 8
Geron Corporation - Pipeline by Stage of Development, 2013 9
Geron Corporation - Monotherapy Products in Pipeline, 2013 10
Geron Corporation - Combination Treatment Modalities in Pipeline, 2013 11
Geron Corporation - Pipeline By Route of Administration, 2013 22
Geron Corporation - Pipeline Products By Mechanism of Action, 2013 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.